NCT05043350 - Combined Antihistaminics Therapy in COVID 19 Patients | Biotech Hunter

Enrollment

214

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

July 30, 2022

Study Completion Date

July 30, 2022

Conditions

Covid19

Interventions

DRUG

Loratadine

107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.

DRUG

Famotidine

107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.

Trial Locations (1)

11765

Nasr City Insurance Hospital, Cairo